Susan Dexter
Technik-/Wissenschafts-/F&E-Leiter bei SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Vermögen: 2 693 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Pankaj Mohan | M | 60 |
Sonnet BioTherapeutics, Inc.
 Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 9 Jahre |
| Donald Griffith | M | 75 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 9 Jahre |
| Jay Cross | M | 53 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 5 Jahre |
| John Cini | M | 72 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 13 Jahre |
| Raghu Rao | M | 62 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 5 Jahre |
| Nailesh Bhatt | M | 52 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 6 Jahre |
| René Fáber | M | 48 | 5 Jahre | |
| Albert Dyrness | M | 61 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 5 Jahre |
| Amy Wilson | F | 53 | 24 Jahre | |
| Anne-Marie Graffin | F | 63 |
Xcellerex, Inc.
 Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | 14 Jahre |
| Lori McNeill | F | 51 | 2 Jahre | |
| Jean-Simon Diallo | M | - |
Virica Biotech, Inc.
 Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | 6 Jahre |
| Terence Anthony Rugg | M | 65 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 6 Jahre |
| Oscar-Werner Reif | M | 59 | 15 Jahre | |
| Pascale Boissel | F | 57 | 5 Jahre | |
| Petra Kirchhoff | F | 55 | - | |
| Ella Korets-Smith | F | - |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | 6 Jahre |
| Joachim Kreuzburg | M | 59 | 17 Jahre | |
| Romaine Fernandes | F | 54 | 21 Jahre | |
| Henri Riey | M | 62 | 17 Jahre | |
| Lothar Kappich | M | 67 | 7 Jahre | |
| Richard Kenney | M | 66 | 3 Jahre | |
| Daniella Kranjac | F | - |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | 3 Jahre |
| Manuel Dafonseca | M | - | 3 Jahre | |
| JonDavid de Jong | M | - |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | 3 Jahre |
| Kenneth Edward Newport | M | 58 |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | 6 Jahre |
| Petra Müller | F | - | - | |
| Beth Thompson-Webb | F | - |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michael Parker | M | 77 | 35 Jahre | |
| Joseph Zakrzewski | M | 60 |
Xcellerex, Inc.
Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | 3 Jahre |
| Wiltrud Treffenfeldt | M | 70 | - | |
| Bernard Lemaître | M | 85 | 12 Jahre | |
| Arnold Picot | M | 79 | 10 Jahre | |
| Liliane de Lassus | M | 80 | 12 Jahre | |
| Joseph Downey | M | 87 | 38 Jahre | |
| Susan Lowther | F | 65 |
Lonza Biologics Plc
 Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | 1 Jahre |
| Richard Donaldson | M | - | 9 Jahre | |
| Humphrey Lee | M | - | 5 Jahre | |
| Patrick Lucy | M | 56 |
Lonza Biologics Plc
Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | 3 Jahre |
| Henry W. Talbot | M | 72 | 10 Jahre | |
| Charles H. Squires | M | - | 5 Jahre | |
| Samuel Smolik | M | 71 | 29 Jahre | |
| Kelly L. S. Arnold | F | - | - | |
| Elin D. Miller | F | 64 | 8 Jahre | |
| Angela Naef | M | - | 9 Jahre | |
| Amanda Parker | F | - | - | |
| Janet Giesselman | F | 69 | 9 Jahre | |
| Wilma Delaney | F | 78 | 27 Jahre | |
| Johanna Söderström | F | 53 | 20 Jahre | |
| Deborah Borg | F | 47 | 15 Jahre | |
| Jeffrey Su | M | - | 1 Jahre | |
| Arjun Permanand Samtani | M | - | 5 Jahre | |
| Amélie Buton | F | 38 | 2 Jahre | |
| Christelle Baudere | F | 49 | 2 Jahre | |
| Phil Sawarynski | M | - | - | |
| James Ringer | M | - | 13 Jahre | |
| Robert McCall | M | 71 | 8 Jahre | |
| Warren G. Clark | M | 76 | 32 Jahre | |
| William L. Curry | M | - | - | |
| William H. Joyce | M | 88 | - | |
| Keith R. McKennon | M | - | 3 Jahre | |
| Keith Marchiando | M | 61 | 6 Jahre | |
| Fernand Joseph Kaufmann | M | 81 | - | |
| Luciano Respini | M | 78 | 4 Jahre | |
| Gregory N. Nelson | M | 68 | 6 Jahre | |
| Gregory J. Heinlein | M | 60 | 12 Jahre | |
| Carol R. Jensen | M | 71 | 3 Jahre | |
| John M. Butler | M | 59 | 4 Jahre | |
| Vicente C. Teixeira | M | 71 | - | |
| Frank P. Popoff | M | 88 | 8 Jahre | |
| Jeff Fettig | M | 67 | 14 Jahre | |
| Richard L. Manetta | M | 79 | - | |
| J. Michael Cook | M | 81 | 6 Jahre | |
| James Ringler | M | 78 | 18 Jahre | |
| Robert Wood | M | 70 | 27 Jahre | |
| Geoffery Merszei | M | 73 | 24 Jahre | |
| Hugh A. Fergusson | M | 76 | - | |
| Carey A. Buckles | M | - | 18 Jahre | |
| Michel Demaré | M | 67 | 5 Jahre | |
| David Grzebinski | M | 62 | 13 Jahre | |
| Preston Johnson | M | 68 | 23 Jahre | |
| William Thomas Austin | M | 73 | - | |
| Carolyn J. Fritz | F | - | 5 Jahre | |
| Mike Masterson | M | - |
Xcellerex, Inc.
Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 59 | 70,24% |
| Frankreich | 15 | 17,86% |
| Kanada | 6 | 7,14% |
| Vereinigtes Königreich | 2 | 2,38% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Susan Dexter
- Persönliches Netzwerk
